Verition Fund Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Verition Fund Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$358K	Buy	+2,800	New	+$350K	﹤0.01%	1709
2024 Q2	–	Sell	-60,100	Closed	-$5.7M	–	3301
2024 Q1	$5.7M	Buy	+60,100	New	+$5.58M	0.04%	585
2022 Q2	–	Sell	-34,000	Closed	-$3.06M	–	3133
2022 Q1	$3.06M	Hold	34,000	–	–	0.04%	669
2021 Q4	$3.81M	Hold	34,000	–	–	0.03%	500
2021 Q3	$4.27M	Buy	+34,000	New	+$4.38M	0.04%	321
2021 Q1	–	Sell	-194,000	Closed	-$27.3M	–	1798
2020 Q4	$27.3M	Buy	194,000 +101,000	+109%	+$12.9M	0.24%	69
2020 Q3	$10.4M	Buy	93,000 +500	+0.5%	+$56.1K	0.21%	76
2020 Q2	$10.4M	Buy	92,500 +57,500	+164%	+$5.66M	0.34%	57
2020 Q1	$2.71M	Sell	35,000 -40,000	-53%	-$3.54M	0.11%	128
2019 Q4	$7.13M	Buy	+75,000	New	+$6.49M	0.13%	120

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Verition Fund Management's XBI Position: Q1 2026 in Review

Verition Fund Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 46% in Q1 2026, selling an estimated $4.79M and leaving 44,776 shares worth $5.72M. The position accounts for 0.04% of the portfolio, ranked #527.

Verition Fund Management first reported a position in XBI in Q2 2013 and has held it in 22 quarters since. The position peaked at $11.5M in Q2 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Verition Fund Management held 44,776 shares of State Street SPDR S&P Biotech ETF worth $5.72M as of Q1 2026.
Verition Fund Management sold 38,400 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.79M.
State Street SPDR S&P Biotech ETF made up 0.04% of Verition Fund Management's portfolio in Q1 2026, its #527 holding.
Verition Fund Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 22 quarters since.
Verition Fund Management's State Street SPDR S&P Biotech ETF position peaked at $11.5M in Q2 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.